-
1
Vinay Prasad has left the FDA for the second time, following a controversial tenure as head of the Center for Biological Evaluation and Research.
-
2
Under the Trump administration, FDA advisory committee meetings on drugs decreased by 72%, raising concerns among rare disease advocates.
-
3
Novo Nordisk plans to reduce the list prices of Ozempic and Wegovy to $675, but generics could be available for as low as $28 annually.
-
4
Parents seek autism diagnoses to gain insurance coverage for treatments like applied behavioral analysis, which can cost $70,000 out of pocket.
-
5
Oregon's new law aims to limit corporate takeovers in healthcare, as community protests arise against PeaceHealth's shift to an Atlanta-based operator.
